SIGMAR1 and Alzheimer disease: The results of the prespecified SIGMAR1 gene variant subgroup analysis reinforce the previously confirmed (from the earlier published Phase 2a AD study [18]) mechanism of action for blarcamesine in AD, beneficial clinical effect through upstream SIGMAR1 activation.